These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 35750415)
1. Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products. Raney SG; Ghosh P; Ramezanli T; Lehman PA; Franz TJ Dermatol Clin; 2022 Jul; 40(3):319-332. PubMed ID: 35750415 [TBL] [Abstract][Full Text] [Related]
2. Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence. Bodenlenz M; Tiffner KI; Raml R; Augustin T; Dragatin C; Birngruber T; Schimek D; Schwagerle G; Pieber TR; Raney SG; Kanfer I; Sinner F Clin Pharmacokinet; 2017 Jan; 56(1):91-98. PubMed ID: 27539717 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products. Raney SG; Franz TJ; Lehman PA; Lionberger R; Chen ML Clin Pharmacokinet; 2015 Nov; 54(11):1095-106. PubMed ID: 26063051 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous Pharmacokinetics of Acyclovir Cream 5% Products: Evaluating Bioequivalence with an In Vitro Permeation Test and an Adaptation of Scaled Average Bioequivalence. Shin SH; Rantou E; Raney SG; Ghosh P; Hassan H; Stinchcomb A Pharm Res; 2020 Oct; 37(10):210. PubMed ID: 33001286 [TBL] [Abstract][Full Text] [Related]
6. Effect of Different Sampling Schedules on Results of Bioavailability and Bioequivalence Studies: Evaluation by Means of Monte Carlo Simulations. Kano EK; Chiann C; Fukuda K; Porta V Drug Res (Stuttg); 2017 Aug; 67(8):451-457. PubMed ID: 28561232 [TBL] [Abstract][Full Text] [Related]
7. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Yacobi A; Shah VP; Bashaw ED; Benfeldt E; Davit B; Ganes D; Ghosh T; Kanfer I; Kasting GB; Katz L; Lionberger R; Lu GW; Maibach HI; Pershing LK; Rackley RJ; Raw A; Shukla CG; Thakker K; Wagner N; Zovko E; Lane ME Pharm Res; 2014 Apr; 31(4):837-46. PubMed ID: 24395404 [TBL] [Abstract][Full Text] [Related]
8. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations. Borsadia S; Ghanem AH; Seta Y; Higuchi WI; Flynn GL; Behl CR; Shah VP Skin Pharmacol; 1992; 5(3):129-45. PubMed ID: 1445703 [TBL] [Abstract][Full Text] [Related]
9. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. N'Dri-Stempfer B; Navidi WC; Guy RH; Bunge AL Pharm Res; 2009 Feb; 26(2):316-28. PubMed ID: 18941872 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic modeling of drug products applied to the skin: A workshop summary report. Tsakalozou E; Alam K; Ghosh P; Spires J; Polak S; Fang L; Sammeta S; Zhao P; Arora S; Raney SG CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):575-584. PubMed ID: 36456539 [TBL] [Abstract][Full Text] [Related]
11. Assessment of cutaneous drug delivery using microdialysis. Kreilgaard M Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S99-121. PubMed ID: 12460718 [TBL] [Abstract][Full Text] [Related]
12. Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. Gwaza L; Gordon J; Welink J; Potthast H; Hansson H; Stahl M; García-Arieta A Eur J Clin Pharmacol; 2012 Dec; 68(12):1611-8. PubMed ID: 23011014 [TBL] [Abstract][Full Text] [Related]
13. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends. Srinivas NR Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891 [TBL] [Abstract][Full Text] [Related]
14. Clinical microdialysis in skin and soft tissues: an update. Schmidt S; Banks R; Kumar V; Rand KH; Derendorf H J Clin Pharmacol; 2008 Mar; 48(3):351-64. PubMed ID: 18285620 [TBL] [Abstract][Full Text] [Related]
15. Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1. Tsakalozou E; Babiskin A; Zhao L CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):399-411. PubMed ID: 33547863 [TBL] [Abstract][Full Text] [Related]
16. Progress in methodologies for evaluating bioequivalence of topical formulations. Shah VP Am J Clin Dermatol; 2001; 2(5):275-80. PubMed ID: 11721645 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. Marston SA; Polli JE Pharm Res; 1997 Oct; 14(10):1363-9. PubMed ID: 9358548 [TBL] [Abstract][Full Text] [Related]
18. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. Au WL; Skinner M; Kanfer I J Pharm Pharm Sci; 2010; 13(1):11-20. PubMed ID: 20456826 [TBL] [Abstract][Full Text] [Related]